An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Table 1 Published US costs of management of symptomatic skeletal events and Grade 3/4 adverse events

Event	Cost	Source of cost^a
Symptomatic skeletal events^b
Radiation to bone	$6460 (€5491)	Carter et al. (2013) [30]
Pathological fracture	$31,387 (€26,679)	Carter et al. (2013) [30]
Spinal cord compression	$46,382 (€39,425)	Carter et al. (2013) [30]
Grade 3/4 adverse events
Asthenia or fatigue	$27 (€23)	Sorensen et al. (2013) [32]
Diarrhea	$8268 (€7028)	Bui et al. (2016 ) [29]^c
Infection	$9689 (€8236)	Bui et al. (2016 ) [29]^c
Musculoskeletal pain or discomfort	$19 (€16)	Sorensen et al. (2013) [32]
Peripheral neuropathy	$748 (€636)	Costing methodology: Bilir et al. (2016 ) [28]^d
Renal disorder	$11,713 (€9956)	Bui et al. (2016) [29]^c
Cardiac disorder	$13,126 (€11,157)	Bui et al. (2016 ) [29]^c
Febrile neutropenia	$18,739 (€15,928)	Bui et al. (2016 ) [29]^c
Anemia	$5063 (€4304)	Sorensen et al. (2013) [32]
Leukopenia	$191 (€162)	Roy et al. (2015) [31]
Neutropenia	$191 (€162)	Roy et al. (2015) [31]
Thrombocytopenia	$1266 (€1076)	Sorensen et al. (2013) [32]
Hyponatremia^e	$1354 (€1151)	Cost of outpatient management: Roy et al. (2015) [31] Cost of inpatient management: Bilir et al. (2016) [28]

Abbreviations: CPT Current Procedural Terminology; LOS length of stay, US United States, USD US dollar
^aReported costs were inflated to 2020 USD using the health component of the Consumer Price Index [33]
^bThe cost for bone surgery was not included as the incidence was 0% for both arms in the CARD trial [25]
^cCosts reported by Bui et al. [29] assumed hospitalization (aligned with clinician input)
^dCost based on CPT 99214 (outpatient visit, $110.43 [€94]) [42] and Red Book [43] cost for pregabalin ($11.19 [€10]). Pregabalin dosage: 300 mg/day for 3 days + 600 mg/day for 27 days
^eAssumed 92.5% outpatient management and 7.5% hospitalization with 3 days of LOS (based on clinician input)

ISSN: 1472-6963